Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hodgkin Disease | 4 | 2021 | 293 | 1.400 |
Why?
|
| Immunoconjugates | 1 | 2023 | 35 | 0.860 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2023 | 44 | 0.850 |
Why?
|
| Telomere Shortening | 1 | 2019 | 34 | 0.640 |
Why?
|
| Telomerase | 1 | 2019 | 165 | 0.610 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 128 | 0.600 |
Why?
|
| Neutropenia | 1 | 2019 | 202 | 0.580 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2024 | 1250 | 0.530 |
Why?
|
| Antineoplastic Agents | 1 | 2023 | 1677 | 0.450 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2024 | 221 | 0.370 |
Why?
|
| Radiation Pneumonitis | 2 | 2022 | 13 | 0.350 |
Why?
|
| Cancer Survivors | 2 | 2022 | 187 | 0.300 |
Why?
|
| Adolescent | 10 | 2024 | 18929 | 0.250 |
Why?
|
| Mutation | 1 | 2019 | 5735 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 174 | 0.220 |
Why?
|
| Burkitt Lymphoma | 1 | 2024 | 146 | 0.200 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2024 | 137 | 0.200 |
Why?
|
| MAP Kinase Signaling System | 1 | 2024 | 320 | 0.200 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 345 | 0.200 |
Why?
|
| Child | 9 | 2024 | 24049 | 0.180 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2024 | 1118 | 0.180 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 137 | 0.170 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 132 | 0.170 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2024 | 525 | 0.170 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2021 | 223 | 0.170 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 1 | 2021 | 144 | 0.170 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2021 | 193 | 0.160 |
Why?
|
| Induction Chemotherapy | 1 | 2018 | 42 | 0.150 |
Why?
|
| Survivors | 1 | 2020 | 345 | 0.150 |
Why?
|
| Neoplasms, Second Primary | 1 | 2019 | 152 | 0.150 |
Why?
|
| Sepsis | 1 | 2021 | 472 | 0.140 |
Why?
|
| Lung | 2 | 2022 | 1477 | 0.140 |
Why?
|
| Incidence | 2 | 2020 | 3004 | 0.130 |
Why?
|
| Stroke | 1 | 2022 | 956 | 0.120 |
Why?
|
| Humans | 13 | 2024 | 122120 | 0.120 |
Why?
|
| Adult | 4 | 2024 | 28676 | 0.120 |
Why?
|
| Severity of Illness Index | 2 | 2019 | 2811 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 4984 | 0.110 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2024 | 160 | 0.100 |
Why?
|
| Female | 8 | 2024 | 64764 | 0.100 |
Why?
|
| Recurrence | 2 | 2024 | 1407 | 0.090 |
Why?
|
| Male | 8 | 2024 | 59429 | 0.090 |
Why?
|
| Prognosis | 1 | 2019 | 4484 | 0.090 |
Why?
|
| Radiotherapy Dosage | 2 | 2022 | 185 | 0.080 |
Why?
|
| Risk Factors | 2 | 2020 | 9864 | 0.080 |
Why?
|
| Neoplasms | 2 | 2022 | 2751 | 0.080 |
Why?
|
| Young Adult | 4 | 2024 | 8772 | 0.070 |
Why?
|
| Diagnosis, Differential | 2 | 2024 | 1872 | 0.070 |
Why?
|
| Child, Preschool | 4 | 2024 | 13781 | 0.060 |
Why?
|
| Adenine Nucleotides | 1 | 2024 | 41 | 0.060 |
Why?
|
| Arabinonucleosides | 1 | 2024 | 32 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2024 | 77 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2024 | 100 | 0.060 |
Why?
|
| Infant | 3 | 2024 | 12304 | 0.050 |
Why?
|
| Organs at Risk | 1 | 2022 | 23 | 0.050 |
Why?
|
| Salvage Therapy | 1 | 2024 | 193 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2022 | 194 | 0.050 |
Why?
|
| Immunity | 1 | 2021 | 182 | 0.040 |
Why?
|
| Autoimmunity | 1 | 2021 | 170 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 169 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2021 | 253 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 234 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2021 | 508 | 0.040 |
Why?
|
| SEER Program | 1 | 2019 | 193 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2024 | 12020 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 663 | 0.040 |
Why?
|
| Genetic Association Studies | 1 | 2021 | 737 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 147 | 0.040 |
Why?
|
| Bleomycin | 1 | 2018 | 150 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2019 | 871 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 1424 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1293 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2021 | 980 | 0.030 |
Why?
|
| Genomics | 1 | 2021 | 1461 | 0.030 |
Why?
|
| Middle Aged | 2 | 2024 | 25538 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 2030 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 18735 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2018 | 15856 | 0.010 |
Why?
|